Brief: Gland Pharma Says US FDA Concludes Surprise Inspection At Dundigal Facility
25/07/2024 08:51
July 25 (Reuters) - Gland Pharma Ltd GLAD.NS :
* CONCLUSION OF US FDA SURPRISE INSPECTION AT DUNDIGAL
FACILITY,
HYDERABAD
* INSPECTION CONCLUDED WITH TWO 483 OBSERVATIONS
* OBSERVATIONS ARE PROCEDURAL IN NATURE
Source text for Eikon: ID:nNSE6jkd57
Further company coverage: GLAD.NS
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant